Navigation Links
Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Date:12/20/2007

REDWOOD CITY, Calif., Dec. 20 /PRNewswire/ -- Pearl Therapeutics, Inc., a biopharmaceutical company developing treatments for major respiratory diseases, today announced the appointment of Colin Reisner, MD, FCCP, FAAAAI to the position of Chief Medical Officer and Executive Vice President of Clinical Development and Medical Affairs, and Michael Golden to the position of Vice President, Regulatory Affairs and Quality.

"We are delighted to welcome Colin and Michael as we continue to build our team with experts in the development of respiratory products," said Adrian Smith, President, Pearl Therapeutics, Inc. "Both Colin and Michael have proven records of success in the pharmaceutical industry and are innovative leaders who have designed and managed the clinical and CMC development programs of many marketed products, from pre-clinical through NDA filing and commercialization."

Dr. Reisner joins Pearl from Novartis Pharmaceuticals where he was Executive Director and former Disease Area Section Head for Global Respiratory Development, a position focused on both clinical development leadership and shaping Novartis' global strategy for respiratory products. He led the clinical development activities of several programs in asthma, COPD, and cystic fibrosis, assessing single and combination therapies across a wide range of delivery systems and dosage forms. Earlier at Novartis, Dr. Reisner served as the Global Brand Medical Director for Xolair(R), the first biologic agent approved for asthma. In this capacity, he oversaw all clinical activities ranging from design and implementation of the pediatric development program to the European approval for the treatment of severe persistent allergic asthma.

Prior to Novartis, Dr. Reisner served as Senior Director in the Respiratory Division at GlaxoSmithKline, and as the International Project Leader for beta agonists. Dr. Reisner played a diverse and integral role in the development of several key product
'/>"/>

SOURCE Pearl Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
5. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
6. Nile Therapeutics, Inc. Adds to Executive Management Team
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
11. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The science of light and how ... more than 200 primary students in a traveling program ... of Otago Physics Department and funded by an ... of the university’s OSA/SPIE Student Chapter visited six primary ... children from small, rural schools hands-on lessons in optics ...
(Date:11/21/2014)... November 20, 2014 The ... Chassis, Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, ... (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast ... market drivers, threats, opportunities, and challenges. , ... figures spread through 185 pages and in-depth ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... Sodium Ferrocyanide Industry” is a professional and in-depth ... provides Sodium ferrocyanide information, like its definition, ... as industry overview. This report covers the international ... as global (such as the US, Europe, Asia, ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... 12 Odyssey Thera, Inc.,announced today that the ... No. 7,306,914, entitled "Protein-fragment Complementation,Assays (PCA) in whole ... infectious disease and gene therapy." This is the,twelfth ... The patent describes a method for detecting protein-protein,interactions ...
... "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of ... First Modules due Before ... ARPN) announced today the enrolment and dosing of the first ... the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) / healthcare-associated ...
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
(Date:11/3/2014)... -- Research and Markets has announced the addition ... and Companies" to their offering. This ... have already started to play an important role in the ... old fashioned bone marrow transplants. Role of cells in drug ... a part of medical practice. Stem cells are ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
... lobe dementia ,Frontal lobe dementia (Frontotemporal Dementia, FTD) ... is the form of dementia that occurs most frequently in ... in the frontal lobe where large numbers of brain cells ... part of the brain and constitutes about 30% of the ...
... J. Craig Venter, Energy Bioscience Institute,s Chris Somerville ... Department of Energy Joint Genome Institute (DOE JGI) ... March 25-27, 2009 in Walnut Creek, Calif. ... of renewable energy strategies, biomass conversion to biofuels, ...
... GAINESVILLE, Fla. Older, active people who have a drink ... according to a report today from a University of Florida ... and Drugs . Although people 50 or older in ... they performed worse on special tests after having moderate amounts ...
Cached Biology News:Blood test predicts chance of dementia 2Venter, Somerville and Church highlight DOE/JGI genomics of energy and environment meeting 2After a few drinks, older adults more impaired than they think 2After a few drinks, older adults more impaired than they think 3
... 48° Fixed Angle Polypropylene Rotor ... Series, IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. ... quiet operation. /MP4, ,EXCLUSIVE polypropylene rotor ... can be repeatedly autoclaved. Polypropylene ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... The Xcise is a powerful technology ... throughput proteome analysis. High quality sample ... untrained user. , The Xcise is a ... for high throughput proteome analysis. It combines ...
Extra Large bottle for hybridization 300 x 70mm...
Biology Products: